While Novo Nordisk ADR has overperformed by 1.68%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVO fell by -26.29%, with highs and lows ranging from $148.15 to $78.17, whereas the simple moving average fell by -27.21% in the last 200 days.
On January 06, 2025, Bernstein Upgraded Novo Nordisk ADR (NYSE: NVO) to Mkt Perform. A report published by Goldman on May 30, 2024, Initiated its previous ‘Buy’ rating for NVO. BMO Capital Markets also rated NVO shares as ‘Outperform’, setting a target price of $163 on the company’s shares in an initiating report dated April 12, 2024. Morgan Stanley Initiated an Overweight rating on January 23, 2024, and assigned a price target of $120. UBS initiated its ‘Neutral’ rating for NVO, as published in its report on January 16, 2024. Cantor Fitzgerald’s report from December 01, 2023 suggests a price prediction of $120 for NVO shares, giving the stock a ‘Overweight’ rating. Argus also rated the stock as ‘Buy’.
Analysis of Novo Nordisk ADR (NVO)
NVO currently pays a dividend of $1.45 per share, which means investors will get a return regardless of the company’s performance over the next few months. Further, the quarter-over-quarter increase in sales is 29.02%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Novo Nordisk ADR’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of 82.03% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.55, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 8.08M can be a very valuable indicator of volatility for NVO stock. On a monthly basis, the volatility of the stock is set at 2.40%, whereas on a weekly basis, it is put at 2.20%, with a gain of 2.14% over the past seven days. Furthermore, long-term investors anticipate a median target price of $118.24, showing growth from the present price of $87.17, which can serve as yet another indication of whether NVO is worth investing in or should be passed over.
How Do You Analyze Novo Nordisk ADR Shares?
The Denmark based company Novo Nordisk ADR (NVO) is one of the biggest names in Drug Manufacturers – General. When comparing Novo Nordisk ADR shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 26.56, there is a growth in quarterly earnings of 28.11%.
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.03%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 9.90% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NVO shares are owned by institutional investors to the tune of 9.90% at present.
